Sofinnova Investments’s OncoMed Pharmaceuticals, Inc. OMED Stock Holding History

Sofinnova Investments’s Portfolio OMED Stock Details OMED Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-395,744	Closed	-$839K	–	77
2018 Q3	$839K	Sell	395,744 -500	-0.1%	-$1.2K	0.07%	60
2018 Q2	$915K	Buy	396,244 +329,211	+491%	+$959K	0.1%	53
2018 Q1	$213K	Buy	+67,033	New	+$185K	0.04%	45

Other funds holding OMED

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Harbourvest Partners Boston, Massachusetts $101M AUM 38.13% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Sofinnova Investments's OMED Position: Q4 2018 in Review

Sofinnova Investments sold out of OncoMed Pharmaceuticals, Inc. (OMED) in Q4 2018, closing a stake of 395,744 shares — an estimated $839K sold.

Sofinnova Investments first reported a position in OMED in Q1 2018 and held it in 3 quarters. The position peaked at $915K in Q2 2018. 42 funds tracked by Wall St. Rank hold OMED as of Q4 2018.

Sofinnova Investments reported no remaining OncoMed Pharmaceuticals, Inc. position as of Q4 2018 after selling out during the quarter.
Sofinnova Investments sold 395,744 OncoMed Pharmaceuticals, Inc. shares in Q4 2018, an estimated $839K.
Sofinnova Investments first reported a position in OncoMed Pharmaceuticals, Inc. in Q1 2018 and held it in 3 quarters.
Sofinnova Investments's OncoMed Pharmaceuticals, Inc. position peaked at $915K in Q2 2018.
42 funds tracked by Wall St. Rank held OncoMed Pharmaceuticals, Inc. as of Q4 2018.

Based on Sofinnova Investments's 13F filing for Q4 2018, filed 14 Feb 2019.